Recent studies have shown that ALOX12–12-HETE pathway was activated both in liver IRI and NASH, but whether ALOX12–12-HETE pathway was activated during IRI in NAFLD remains unknown. Here, ALOX12 is linked to metabolic dysfunction-associated steatohepatitis.